Science Avizorex pharma

Dry Eye Disease (DED) is a multifactorial disease characterized by an inability to produce tears of sufficient quantity and quality to allow for adequate lubrication and protection of the eye surface. It causes unpleasant dryness, discomfort or pain sensations, increased tear film osmolarity, disturbed vision, inflammation, corneal scarring and in the most severe cases, loss of vision.  DED is the most common ocular disease in the world, afflicting more than 5% of the human population, with a particular incidence among elderly people where prevalence reaches values of around 35% .


The company develops novel pharmacological treatments for the treatment of DED, based on the manipulation of the neural mechanisms that regulate the volume of tear fluid secreted by the lacrimal glands, and evoke the discomfort sensations elicited by ocular surface dryness, the two main mechanisms that are impaired in DED and are responsible of  the signs and symptoms observed in DED patients.